TorEx Lung Perfusion System; TorEx Lung Perfusate
Traferox Technologies, Inc. · Decision date Oct 30, 2026
What did the FDA approve?
FDA records P250025/S002 as a supplement to PMA P250025, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Oct 30, 2026.
FDA approval order statement
Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P250025.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 30, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P250025/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Traferox Technologies, Inc.
- Product code
- PHO
- Decision code
- APPR
- Decision date
- Oct 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.
- Applicant
- Traferox Technologies, Inc.
- Product code
- PHO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250025. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250025 · Original PMA
TorEx Lung Perfusion System
P250025/S002 received
Application receipt date recorded by FDA.
P250025/S001 · Related supplement
TorEx Lung Perfusion System; TorEx Lung Perfusate
P250025/S002 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P250025. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250025
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TorEx Lung Perfusion SystemP250025 | Traferox Technologies, Inc. | PMA approval | Jul 15, 2026 | FDA |
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code PHO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LungFX DeviceP240033/S001 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
LungFX DeviceP240033/S002 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
XPS with Steen Solution PerfusateP180014/S014 | Xvivo Perfusion, Inc. | PMA supplement | Sep 16, 2026 | FDA |
LungFX deviceP240033 | Lung Bioengineering, Inc. | PMA approval | Jun 22, 2026 | FDA |
| Xvivo Perfusion, Inc. | PMA approval | Apr 26, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Traferox Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3505 Laird Rd., Unit 16, Mississauga, L5L 5Y7
Sources and methodology
- Original FDA record: P250025/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




